7 results
Primary:• Arm 1: To determine the maximum-tolerated dose (MTD) and doselimitingtoxicity (DLT) of single agent LBY135 and LBY135 when administered in combinationwith capecitabine to adult patients with advanced solid tumorsSecondary:• To characterize…
Primary1. To assess the hematologic response and return to chronic phase rate in patients with accelerate phase or blasts crisis whose diseae is resistant following treatment with at lest two BCR-ABL tyrosine kinase inhibitors when treated with…
PrimaryTo determine the hematological response (complete response(CR) / partial response (PR)) rate as per Bladé criteria to treatment with oral LBH589 of patients with MM who have received at least two prior lines of therapy and whose disease is…
1) To assess the antitumor activity of PHA-739358 administered as IV infusion according to two different dose schedules in metastatic HRPC patients progressing on standard docetaxel-based chemotherapy.2) To have a precise idea of the antitumor…
To compare the short-term and long-term clinical efficacy, safety and tolerability of ABT-874 compared to MTX in the treatment of moderate to severe chronic plaque psoriasis over a 24 and 52-week period.
Primary objective (dose escalation arm): To determine the MTD of AUY922 as a single agent.Primary objective (phase II): At the MTD two further arms will be expanded to assess response (breast cancer)
To assess the long-term safety, tolerability and efficacy of ABT-874 in adults who have either completed or have demonstrated a loss of response (as defined in the original ABT-874 protocol) to treatment in a preceding ABT-874 study in the treatment…